Pharma Business - May 12, 2026
Bavarian Nordic awarded contract options from US Government
The Center for the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS), has exercised additional options valued at USD 97 million under the existing contract to supply a freeze-dried formulation of JYNNEOS smallpox vaccine.
CDMO - April 23, 2026
CEPI awards seed funding to Analysis Zero
CEPI and the Recipharm company Analysis Zero have announced a new seed collaboration to advance the use of Nuclear Magnetic Resonance (NMR) as a real-time Process Analytical Technology (PAT) for RNA vaccine manufacturing.
CDMO - April 21, 2026
Nanologica receives SEK 2 million order from customer in India
Nanologica has received an order of appx. SEK 2 million for the company’s silica-based purification media NLAB Saga.
Biotech article - April 20, 2026
In focus: Nasal drug delivery for quicker uptake
Nasal drug delivery is a dynamic area in pharmaceutical innovation. What was once a route for decongestants and allergy sprays is now being explored for everything from emergency treatments to vaccines – and even shows potential for future central nervous system therapies.
Pharma article - April 11, 2026
Alfa Laval sharpens focus on serving pharmaceutical production
Alfa Laval has implemented a transformation of its organization to establish the Food & Pharma Division.
COVID-19 - April 7, 2026
NLS Insight: The new COVID‑19 variant “Cicada”
A new COVID‑19 variant nicknamed Cicada (BA.3.2) is spreading internationally, with early data indicating notable immune escape but no clear evidence of more severe disease than current strains.